Aurora Spine Surpasses Milestone of 2,500 Procedures Using SiLO(TM) SI Joint Fusion System
MWN-AI** Summary
Aurora Spine Corporation, a leader in innovative spinal solutions, has announced a significant achievement, surpassing 2,500 procedures using its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System as of June 10, 2025. This milestone highlights the growing acceptance and adoption of Aurora’s minimally invasive technology among surgeons across the United States. As outlined by CEO Trent Northcutt, this achievement showcases the market's response to the SiLO™ platform and signifies promising growth potential as the company invests in innovation, education, and operational execution.
The SiLO™ system, including the SiLO-TFX™ variant, is specifically designed to address SI joint pain and dysfunction through a posterior approach, which enhances fixation stability and reduces recovery time. Surgeons report high patient satisfaction and improved outcomes, underscoring the system's clinical advantages. Dr. Michael Stoffman, a neurosurgeon, noted the intuitive design of the SiLO-TFX™ system, facilitating consistency and precision during procedures.
Key factors driving Aurora’s growth include the expansion of its U.S. sales network and targeted educational initiatives for surgeons. The company also develops a robust portfolio with additional innovative products like the AERO™ Facet Fusion System and DEXA TECHNOLOGY™-matched interbody implants, tailored to patients' unique bone densities.
Aurora Spine remains committed to advancing the field of minimally invasive spinal treatment, focusing on delivering superior patient outcomes supported by clinical research. With positive feedback from the surgical community and ongoing advancements, the company aims to lead the evolution of spine care through design excellence and scientific evidence, thereby establishing a solid foundation for future innovations in spinal surgery.
MWN-AI** Analysis
Aurora Spine Corporation's recent announcement of surpassing 2,500 procedures using its SiLO™ Sacroiliac Joint Fusion System is a significant milestone that indicates robust market growth and increasing acceptance of its innovative spinal solutions. This development not only signals a strong validation of Aurora's technology by the medical community but also points to the company's potential for scalability and profitability in the rapidly evolving minimally invasive spine surgery market.
Analysts should consider several key elements when evaluating Aurora Spine's investment potential. First, the growing adoption of the SiLO™ system, with positive feedback from surgeons regarding its clinical advantages, underscores its competitive edge in the marketplace. Surgeons are increasingly looking for solutions that provide not only efficacy but also enhanced patient outcomes, which SiLO™ is reportedly achieving.
Aurora’s expanding U.S. sales network and targeted surgeon education programs are further catalysts driving its market penetration. By effectively educating healthcare providers about the benefits and functionalities of its products, Aurora can enhance adoption rates and, ultimately, its revenue generation.
Additionally, the launch of complementary innovations like the AERO™ Facet Fusion System and DEXA TECHNOLOGY™-matched implants further diversifies Aurora's portfolio, reducing reliance on any single product and appealing to a broader spectrum of patient needs. The continuous flow of peer-reviewed publications bolsters credibility, reinforcing the evidence behind Aurora's offerings.
Investors should remain aware, however, of potential risks. The company operates in a highly regulated environment, and advancements may face challenges from competitors and regulatory hurdles. Furthermore, while the company's trajectory appears positive, the reliance on forward-looking statements necessitates caution.
In conclusion, Aurora Spine presents a compelling investment opportunity for those seeking exposure to innovative healthcare technologies, provided they remain cognizant of the inherent risks associated with the medical device industry.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARLSBAD, CALIFORNIA, June 10, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF) , a pioneer in innovative spinal solutions, proudly announces that its proprietary SiLO™ Sacroiliac (SI) Joint Fusion System has been successfully used in over 2,500 procedures across the United States. This major milestone underscores the company’s accelerating growth and increasing adoption of its minimally invasive technology by surgeons nationwide.
Aurora’s SiLO™ platform, which includes the SiLO-TFX™ system, is engineered to improve outcomes for patients suffering from SI joint pain and dysfunction. Utilizing a posterior approach, the system enables secure transfixation across the SI joint, delivering enhanced fixation, reduced recovery times, and consistently high patient satisfaction.
“This milestone is a key indicator of market acceptance and commercial scalability,” said Trent Northcutt, CEO of Aurora Spine. “SiLO™ is resonating with surgeons who want smarter solutions, and this is only the beginning. Our commitment to innovation, education, and execution continues to unlock meaningful growth opportunities.”
Key Drivers of Growth:
- 2,500+ SiLO™ Procedures Performed Nationwide
- Rapid expansion of Aurora’s U.S. sales network
- Launch of targeted surgeon education programs
- Continued innovation across the minimally invasive spine portfolio
The SiLO-TFX™ system has gained traction due to its intuitive instrumentation and reproducible outcomes, as reflected in glowing feedback from the surgical community:
“The SiLO-TFX™ system offers unprecedented clinical advantages in my practice,” said Dr. Michael Stoffman, MD, Neurosurgeon. “The instrumentation is intuitive, precise, and designed with the surgeon’s workflow in mind, allowing for consistent, reproducible outcomes and improved patient recovery.”
In addition to the SiLO™ platform, Aurora’s growing suite of innovations includes the AERO™ Facet Fusion System and the DEXA TECHNOLOGY™-matched interbody implants—the world’s first spinal implants customized to a patient’s bone density.
“Our goal is to provide the most effective and least invasive treatment options, supported by robust clinical evidence,” said Matthew Goldstone, Chief Commercial Officer. “We’re proud to have multiple peer-reviewed publications in 2025, with more on the horizon. Clinical data is the key to shaping the future of spine care.”
“Aurora Spine leads in spine innovation with our SiLO™ platform, which has now surpassed 2,500 procedures,” added Laszlo Garamszegi, Chief Technology Officer. “Positive feedback from surgeons and patients continues to inspire us as we introduce advanced technologies like AERO™ and DEXA-based implants. We're committed to driving the future of minimally invasive spine treatments through design excellence and clinical science.”
Aurora Spine remains focused on delivering groundbreaking spinal technologies that empower surgeons, improve patient outcomes, and lead the evolution of minimally invasive spine surgery.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Company Contacts: Aurora Spine Corporation
Trent Northcutt
?President and Chief Executive Officer
?(760) 424-2004
Chad Clouse
?Chief Financial Officer
?(760) 424-2004
? www.aurora-spine.com
Investor Contact:
Adam Lowensteiner
??Lytham Partners
??(646) 829-9702
Email: asapf@lythampartners.com
NASDAQ: ASG:CC
ASG:CC Trading
-2.74% G/L:
$0.355 Last:
1,000 Volume:
$0.375 Open:
